Business
Novavax Appoints Biopharmaceutical Veterans Jim Kelly as Chief Financial Officer and Nasir Egal, Ph.D., as Senior Vice President of Quality Assurance
GAITHERSBURG, Md., Aug. 16, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious
About this update from Novavax, Inc.
[{"type":"text","content":"GAITHERSBURG, Md., Aug. 16, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Jim Kelly as Executive Vice President, Chief Financial Officer (CFO) and Treasurer, and Nasir Egal, Ph.D. as Senior Vice President, Quality Assurance. Mr. Kelly will report to Stanley C. Erck, President and Chief Executive Officer, and Dr. Egal will report to Rick Crowley, Executive Vice President and Chief Operations Officer.\nMr. Kelly brings more than twenty-five years of industry experience in both commercial and clinical-stage companies to Novavax. He joins Novavax from Supernus Pharmaceuticals, where he served as CFO. Previously, he spent ten years at Vanda Pharmaceuticals, where he was CFO and Treasurer. Earlier, he spent over a decade in finance roles of increasing responsibility at MedImmune (now AstraZeneca) and Biogen. He holds a Master of Business Administration from Cornell University, a Bachelor of Science in Business Administration from the University of Vermont and is a CFA charterholder.\n\"We welcome Jim's broad finance and strategic leadership as Novavax quickly matures into a global commercial company,\" said Mr. Erck. \"His experience will be of particular importance as we prepare to effectively deliver urgently needed vaccine to all corners of the world in the fight against COVID-19 and work to advance our pipeline of vaccine candidates targeting serious infectious diseases.\"\nDr. Egal brings a diverse range of global quality experience to Novavax. He most recently served as the Head of Global Quality External Affairs at Sanofi, where he spent nearly a decade in roles of increasing responsibility. Earlier in his career, he held global and regional quality and compliance roles at Novartis and Merck. He also spent time at the United States Food and Drug Administration as a research scientist. Egal holds a Doctorate in Chemistry from the American University. \n\"Nasir's deep quality experience and perspective gained by leading complex global programs will be invaluable as we continue to advance regulatory and commercial activities for our recombinant nanoparticle COVID-19 vaccine,\" said Mr. Crowley. \"Nasir brings invaluable quality expertise at precisely the right time for Novavax.\"\nAbout NovavaxNovava...